The Translational Research Program (TRP) puts you on the bench-to-bedside fast track when it comes to finding better treatment and cures for leukemia, lymphoma and myeloma. The Leukemia & Lymphoma Society funds new and innovative research that shows high promise for translating basic biomedical knowledge to clinical application.
Applicant citizenship: Worldwide
Host country: Worldwide
Years since PhD: NA
Award: USD 216 666.66
Award Duration (years): 3
Research costs:
Benefits:
Mobility rule: No
Subjects: Life Sciences , Medicine and Health Sciences
Additional comments: The formation of the Translational Research Program (TRP) was to enhance the transfer of basic research findings to clinical usefulness. Applications are sought proposing novel approaches to the prevention, diagnosis or treatment of hematological malignancies and related pre-malignant conditions. Proposals should be based on molecular, cellular or integrated systems findings and be conceptually innovative. The application should have a clear plan for the eventual clinical translation of the studies proposed and the results expected. This feature will be an important consideration of the review process. This program is intended to provide support over an initial three-year period. Two additional years may be available through the competitive, peer-reviewed TRP Renewal process to solidify progress made in the initial award and further support a clinical trial. To be considered for a TRP renewal award, a clinical protocol for a Phase I or Phase II clinical trial based on the initial TRP grant must be submitted to the institution’s IRB for approval and the work must be a direct result of the funded TRP award (see Renewal Guidelines and Instructions for detailed information).
How to apply? For further eligibility requirements and the application process, please visit: Official Funding website
This entry has been last updated: 2020-05-24 15:46:36